Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1955 1
1956 1
1957 3
1958 1
1959 1
1960 2
1961 1
1962 4
1963 9
1964 17
1965 6
1966 5
1967 10
1968 1
1969 8
1970 7
1971 6
1972 3
1973 2
1975 3
1976 6
1977 3
1978 3
1979 11
1980 8
1981 12
1982 12
1983 17
1984 21
1985 17
1986 27
1987 29
1988 28
1989 12
1990 29
1991 25
1992 26
1993 23
1994 17
1995 22
1996 18
1997 15
1998 14
1999 24
2000 21
2001 31
2002 36
2003 41
2004 45
2005 70
2006 67
2007 58
2008 53
2009 49
2010 66
2011 65
2012 68
2013 72
2014 74
2015 72
2016 54
2017 60
2018 44
2019 39
2020 51
2021 45
2022 27
2023 35
2024 31
2025 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,701 results

Results by year

Filters applied: . Clear all
Page 1
Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact.
MacLeod M, Papi A, Contoli M, Beghé B, Celli BR, Wedzicha JA, Fabbri LM. MacLeod M, et al. Respirology. 2021 Jun;26(6):532-551. doi: 10.1111/resp.14041. Epub 2021 Apr 24. Respirology. 2021. PMID: 33893708 Free article. Review.
In chronic obstructive pulmonary disease (COPD), exacerbations (ECOPD), characterized by an acute deterioration in respiratory symptoms, are fundamental events impacting negatively upon disease progression, comorbidities, wellbeing and mo …
In chronic obstructive pulmonary disease (COPD), exacerbations (ECOPD), characterized by an acute deterio …
Chronic bronchitis and chronic obstructive pulmonary disease.
Kim V, Criner GJ. Kim V, et al. Am J Respir Crit Care Med. 2013 Feb 1;187(3):228-37. doi: 10.1164/rccm.201210-1843CI. Epub 2012 Nov 29. Am J Respir Crit Care Med. 2013. PMID: 23204254 Free PMC article. Review.
Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD). ...Despite its clinical sequelae, little is known about the pathophysiology of CB and goblet cell hyperplasia in COPD, and …
Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease ( …
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. Crocetti L, et al. Molecules. 2022 Aug 4;27(15):4964. doi: 10.3390/molecules27154964. Molecules. 2022. PMID: 35956914 Free PMC article. Review.
Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the treatment of inflammation-based diseases. ...The transition from pre-clinical to clinical phase was not easy for the majority of these compounds, mainly due to their significant side ef …
Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the treatment of inflammation-based diseases. ... …
Ensifentrine: First Approval.
Keam SJ. Keam SJ. Drugs. 2024 Sep;84(9):1157-1163. doi: 10.1007/s40265-024-02081-w. Epub 2024 Aug 28. Drugs. 2024. PMID: 39196510 Review.
Ensifentrine, an inhaled, selective phosphodiesterase (PDE) 3 and PDE4 inhibitor, is being developed by Verona Pharma plc for the treatment of respiratory diseases, including chronic obstructive pulmonary disease (COPD). In June 2024, ens …
Ensifentrine, an inhaled, selective phosphodiesterase (PDE) 3 and PDE4 inhibitor, is being developed by Verona Pharma plc for the tre …
COPD exacerbations: defining their cause and prevention.
Wedzicha JA, Seemungal TA. Wedzicha JA, et al. Lancet. 2007 Sep 1;370(9589):786-96. doi: 10.1016/S0140-6736(07)61382-8. Lancet. 2007. PMID: 17765528 Free PMC article. Review.
Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality. ...Some patients are particularly susceptible to exacerbations, and show worse health status and …
Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, lead …
Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
Parikh N, Chakraborti AK. Parikh N, et al. Curr Med Chem. 2016;23(2):129-41. doi: 10.2174/0929867323666151117121334. Curr Med Chem. 2016. PMID: 26572614 Review.
The PDE4 enzyme has been proven to be a versatile drug target for therapeutics to treat diverse disease conditions such as asthma, COPD, diabetes, Huntington's disease, and various other inflammatory disorders. The treatment of COPD is the most studied …
The PDE4 enzyme has been proven to be a versatile drug target for therapeutics to treat diverse disease conditions such as asthma, …
Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry.
Tello K, Yogeswaran A, Majeed RW, Kiely DG, Lawrie A, Brittain E, Annis JS, Olschewski H, Kovacs G, Hassoun PM, Balasubramanian A, Konswa Z, Sweatt AJ, Zamanian RT, Wilkins MR, Howard L, Arvanitaki A, Giannakoulas G, Cajigas HR, Frantz R, Williams PG, Frauendorf M, Marquardt K, Antoine T, Fuenderich M, Richter M, Grimminger F, Ghofrani HA, Wilhelm J, Seeger W; Pulmonary Vascular Research Institute GoDeep Consortium. Tello K, et al. Chest. 2025 Jan;167(1):224-240. doi: 10.1016/j.chest.2024.08.016. Epub 2024 Sep 7. Chest. 2025. PMID: 39182575
BACKGROUND: Patients with COPD frequently demonstrate pulmonary hypertension (PH). Severe PH in patients with COPD, identified by pulmonary vascular resistance (PVR) of > 5 Wood units (WU), is closely linked to impaired transplant-free survival. ... …
BACKGROUND: Patients with COPD frequently demonstrate pulmonary hypertension (PH). Severe PH in patients with COPD, ide …
Advances in the development of phosphodiesterase-4 inhibitors.
Li G, He D, Cai X, Guan W, Zhang Y, Wu JQ, Yao H. Li G, et al. Eur J Med Chem. 2023 Mar 15;250:115195. doi: 10.1016/j.ejmech.2023.115195. Epub 2023 Feb 9. Eur J Med Chem. 2023. PMID: 36809706 Review.
PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases, including asthma, chronic obstructive pulmonary disease (COPD) and psoriasis. ...Although many PDE4 inhibitors have been approved to en …
PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases, including asthma, chronic o …
Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD.
Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ. Sciurba FC, et al. Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27. Chest. 2025. PMID: 39197510 Free article. Clinical Trial.
BACKGROUND: Exacerbations in COPD can be life-threatening and can lead to irreversible declines in lung function and quality of life. ...Reductions in the rate and risk of exacerbations generally were consistent across patient subgroups, including age, sex, race, backgroun …
BACKGROUND: Exacerbations in COPD can be life-threatening and can lead to irreversible declines in lung function and quality of life. …
[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors].
Sezgi C, Şenyiğit A. Sezgi C, et al. Tuberk Toraks. 2011;59(3):285-90. doi: 10.5578/tt.2460. Tuberk Toraks. 2011. PMID: 22087527 Free article. Review. Turkish.
Chronic obstructive pulmonary disease (COPD) is a disease which is characterized with progressive airflow obstruction and abnormal inflammatory response caused by noxious gases and particles. ...In this review we discussed roflumilast (Da …
Chronic obstructive pulmonary disease (COPD) is a disease which is characterized with progressive …
1,701 results